Elrexfio (elranatamab)
Research Synopsis
- - Elrexfio (elranatamab) is a newly FDA-approved bispecific T-cell engager designed for treating relapsed or refractory multiple myeloma, targeting B-cell maturation antigen (BCMA) and activating T cells to eliminate myeloma cells.
- - Clinical trials, particularly the MagnetisMM-3 trial, have demonstrated that Elrexfio is effective in improving overall survival and response rates in patients who have undergone multiple lines of therapy.
- - A real-world comparison showed that patients treated with Elrexfio achieved higher objective response rates and longer progression-free survival compared to standard physician's choice treatments.
- - Recent case reports highlight success in treating unique cases of multiple myeloma, such as CNS involvement and patients undergoing dialysis, with Elrexfio displaying a favorable safety profile.
- - Patient-reported outcomes indicate that Elrexfio treatment may lead to early improvements in quality of life, with significant percentages of patients reporting reduced symptoms and better health outlooks shortly after starting therapy.
- - The treatment landscape for multiple myeloma continues to evolve, with ongoing research exploring the combination of bispecific antibodies like Elrexfio with existing therapies to optimize outcomes and manage treatment resistance.
- - Concerns about infection risks have been noted in patients receiving bispecific antibodies like Elrexfio, underlining the necessity for continuous monitoring and careful management of immune responses.
- - Elrnatamab is currently under international review, with expectations for approvals in other regions, including Europe and Japan, indicating a step forward in global treatment options for multiple myeloma.
- - Future studies are planned to fully explore Elrexfio's long-term efficacy, safety, and potential integration into combination therapies, aiming to enhance clinical outcomes for patients with difficult-to-treat multiple myeloma.
Elrexfio (elranatamab)
Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma.
London, UK
2 hours ago
1 Received
- Multiple myeloma is a serious blood cancer where plasma cells grow uncontrollably in the bone marrow.
- ELREXFIO™ is a new FDA-approved treatment that helps fight this cancer, specifically targeting the tumor environment and stimulating the immune system.
- Clinical trials have shown that ELREXFIO is effective and well-tolerated, providing new hope for patients dealing with difficult-to-treat multiple myeloma cases.
$100 - $150
Hourly Rate
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
London, UK
2 hours ago
1 Received
- * New T-cell therapies, like bispecific antibodies and CAR-T cells, are promising for MM but their effectiveness for CNS involvement is not well-studied.
- * A case report highlights a 37-year-old male with CNS-MM who was successfully treated with Elranatamab, a bispecific antibody targeting BCMA and CD3.
$100 - $150
Hourly Rate
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
London, UK
2 hours ago
1 Received
- - The treatment landscape for multiple myeloma has advanced significantly in the 21st century, thanks to new drugs like proteasome inhibitors and immunomodulators, as well as immunotherapies introduced in recent years.
- - Recent immunotherapeutic agents include bispecifics and CAR T-cell therapies, which have greatly increased the five-year survival rate for patients to nearly 60% and improved their quality of life.
- - Despite these advancements, multiple myeloma remains incurable as patients often become resistant to treatments and relapse, prompting ongoing research into new therapies and their potential benefits and challenges.
$100 - $150
Hourly Rate
Elranatamab: First Approval.
London, UK
2 hours ago
1 Received
- Elranatamab, developed by Pfizer, is a bispecific T cell engager targeting B-cell maturation antigen (BCMA) to treat multiple myeloma (MM) by activating T cells to kill myeloma cells.
- It received its first approval in August 2023 in the USA for adult patients with relapsed or refractory multiple myeloma who have undergone multiple prior therapies.
- Elranatamab is also under review internationally, including in the EU and Japan, and ongoing clinical studies are being conducted worldwide to further assess its effectiveness.
$100 - $150
Hourly Rate
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
London, UK
2 hours ago
1 Received
- New therapies for multiple myeloma, like monoclonal antibodies daratumumab and isatuximab, have significantly improved patient outcomes, but more patients are becoming resistant to treatments earlier in their disease.
- The rise of triple- or multi-refractory multiple myeloma (MM) highlights a significant medical need, complicating treatment options for these patients.
- Recent advancements in immunotherapy, such as conjugated and bispecific antibodies and CAR T cells, show potential but come with challenges in patient selection and therapy sequencing, prompting ongoing research and clinical trials.
$100 - $150
Hourly Rate
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
London, UK
2 hours ago
1 Received
- Two BCMA-directed CAR-T therapies (ide-cel and cilta-cel) have been approved by the FDA for treating relapsed or refractory multiple myeloma after multiple prior treatments, showing strong results but still facing challenges like relapses and safety in advanced cases.
- * There are concerns about the effectiveness of CAR-T therapy after previous BCMA targeting, prompting interest in using CAR-T earlier in treatment when patients might respond better.
- * Recent trials (CARTITUDE-4 and KarMMA-3) have indicated that earlier use of CAR-T can lead to improved survival rates, and experts are exploring how to best sequence these therapies for optimal patient outcomes.
$100 - $150
Hourly Rate
Antibodies to watch in 2024.
London, UK
2 hours ago
1 Received
- The 'Antibodies to Watch' series gives an annual overview of monoclonal antibody therapeutics that are either in late-stage development, undergoing regulatory review, or have recently been approved, focusing on 16 antibodies granted approval in 2023.
- It also highlights nearly 50 additional product candidates that are either awaiting approval or expected to enter review by the end of 2024, featuring innovative types like bispecific antibodies and antibody-drug conjugates.
- Finally, the article discusses the clinical approval success rates of these antibody therapeutics, which range from 14-32%, indicating that the biopharmaceutical industry is actively advancing and finding success in developing these treatments, especially for non-cancer conditions.
$100 - $150
Hourly Rate
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
London, UK
2 hours ago
1 Received
- - Elranatamab, a new bispecific antibody targeting BCMA and CD3, was approved in August 2023 for treating triple-class exposed/refractory multiple myeloma (TCE/R MM) and showed promising results in the Phase 2 MagnetisMM-3 trial.
- - A matching-adjusted indirect comparison (MAIC) was conducted to evaluate elranatamab's effectiveness against physician's choice of treatment (PCT) by adjusting patient data from MagnetisMM-3 to real-world data from LocoMMotion and MAMMOTH studies.
- - Results indicated elranatamab significantly outperformed PCT, showing higher objective response rates, complete response rates, and longer
$100 - $150
Hourly Rate
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
London, UK
2 hours ago
1 Received
- Bispecific antibodies targeting B-cell maturation antigen and a specific G-protein-coupled receptor have shown significant effectiveness in treating difficult cases of multiple myeloma.
- * Recently, teclistamab, elranatamab, and talquetamab were fast-tracked for approval by health agencies due to their success in heavily pretreated patients.
- * Ongoing challenges include figuring out the best dosing, scheduling, and combination with existing treatments, as well as understanding how tumors evade the immune system.*
$100 - $150
Hourly Rate
A pivotal decade for bispecific antibodies?
London, UK
2 hours ago
1 Received
- Bispecific antibodies (bsAbs) are an advanced type of antibodies that can target two different antigens, offering new treatment mechanisms compared to traditional monoclonal antibodies (mAbs).
- Since the early days of mAbs in the 1980s and 1990s, only a limited number of bsAbs were approved initially, but the count has increased significantly, with 11 approvals after 2020, mainly for cancer treatments.
- Despite being a newer class, some bsAbs, like emicizumab and faricimab, have become top-selling drugs, indicating their growing importance in treating various diseases, including cancers and non-cancer conditions.
$100 - $150
Hourly Rate
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
London, UK
2 hours ago
1 Received
- Relapsed or refractory multiple myeloma (RRMM) significantly affects patients' health-related quality of life (QOL), causing both physical and emotional burdens.
- An analysis of patient-reported outcomes (PROs) from the MagnetisMM-3 study on elranatamab showed early improvements in symptoms, such as reduced pain and better health outlooks for patients new to and those previously treated with BCMA therapy.
- Approximately 40.2% of BCMA-naive and 52.6% of BCMA-exposed patients reported feeling 'a little better' or 'much better' by Cycle 1, Day 15, indicating that elranatamab not only offers clinical benefits but may also enhance
$100 - $150
Hourly Rate
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
London, UK
2 hours ago
1 Received
- For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), B-cell maturation antigen and CD3-directed bispecific antibodies like teclistamab and elranatamab are emerging as new treatment options due to limited existing therapies.
- Teclistamab received conditional approval in Europe and accelerated FDA approval based on the MajesTEC-1 trial, while elranatamab was approved by the FDA following the MagnetisMM-3 trial.
- An indirect comparison showed that elranatamab outperformed teclistamab in terms of objective response rate and progression-free survival, suggesting it may be a more effective treatment for TCE/RMM patients.
$100 - $150
Hourly Rate
Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis.
London, UK
2 hours ago
1 Received
- - The case discusses a patient with relapsed IgA and lambda free light chain multiple myeloma who was on dialysis and treated with elranatamab, a bispecific antibody.
- - The treatment was found to be feasible even with the patient's severe kidney impairment, and it did not result in any unexpected side effects.
- - It highlights the importance of monitoring for infectious risks in patients who are both immunocompromised and have renal issues.
$100 - $150
Hourly Rate
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
London, UK
2 hours ago
1 Received
- Bispecific antibodies (BsAbs) are used to treat relapsed or refractory multiple myeloma, but frequent infections were noted during clinical trials, indicating a need for further real-world data on infection risks and outcomes.
- A multicenter retrospective study involving 229 patients in France from December 2020 to February 2023 found a high incidence of infections, with 234 recorded cases, primarily affecting the respiratory system, and a hospitalization rate of 56%.
- The study identified corticosteroids used for managing cytokine release syndrome as a risk factor for infections, while using GPRC5D-targeting BsAbs and antibacterial prophylaxis was associated with a reduced risk.
$100 - $150
Hourly Rate
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.
London, UK
2 hours ago
1 Received
- - The treatment landscape for multiple myeloma (MM) has changed significantly with the introduction of immunotherapy, particularly through novel therapies targeting tumor antigens.
- - Bispecific antibodies (bsAbs) are a key advancement in antibody-based therapies, showing impressive effectiveness and acceptable safety in relapsed/refractory MM cases.
- - The review discusses the recent approval of bsAbs like elranatamab and teclistamab, focusing on their antigen targeting strategies, efficacy, safety, and insights from clinical trials and real-world data.
$100 - $150
Hourly Rate
A tertiary care centre experience with Elranatamab: A report of three cases.
London, UK
2 hours ago
1 Received
- The introduction of new treatments like proteasome inhibitors and monoclonal antibodies has significantly improved life expectancy for multiple myeloma patients, but there's a need for better therapies, particularly for those with triple-class refractory disease.
- Elranatamab, a bispecific antibody, is commonly used in India for treating this condition, though data on its effectiveness in real-world settings is lacking.
- In a small case report of three patients receiving elranatamab monotherapy, common side effects included mild cytokine release syndrome and cytopenias, with one patient experiencing severe neurological toxicity, highlighting the need for ongoing assessment of treatment safety and efficacy.
$100 - $150
Hourly Rate
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
London, UK
2 hours ago
1 Received
- - In the MagnetisMM-3 trial, the efficacy of elranatamab was compared to physician's choice treatment for patients with triple-class refractory multiple myeloma, showing promising results for the new therapy.
- - Analysis of two oncology databases (COTA and Flatiron Health) revealed that patients treated with elranatamab had a higher objective response rate, longer progression-free survival, and better overall survival compared to those receiving standard physician-selected treatments.
- - Elranatamab demonstrated significant benefits for BCMA-naive patients, suggesting it may be a more effective option compared to treatments commonly used in clinical practice.
$100 - $150
Hourly Rate